

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **JBM (Healthcare) Limited**

**健倍苗苗 (保健) 有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2161)**

### **POSITIVE PROFIT ALERT**

This announcement is made by JBM (Healthcare) Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors (the “**Director(s)**”) of the Company (the “**Board**”) wishes to inform shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 September 2024 and the information currently available to the Board, the Group expects that the consolidated profit attributable to Shareholders for the six months ended 30 September 2024 (“**Consolidated Profit**”) increased by not less than 50% as compared with the same period of last year.

The significant increase in Consolidated Profit was primarily driven by the robust sales momentum of the Group’s key brands, notably Ho Chai Kung in the branded medicines segment and Po Chai Pills in the proprietary Chinese medicines segments. This was further supported by the sustained growth of the Group’s concentrated Chinese medicine granules business. This encouraging performance reflects our effective execution of sales and marketing strategies across both offline and online channels, capitalising on the growth potential of branded consumer healthcare products in the markets of Hong Kong, Macau, and cities within the Greater Bay Area.

As at the date of this announcement, the consolidated results of the Group for the six months ended 30 September 2024 have not yet been finalised. The information contained in this announcement is only based on a preliminary assessment by the Board with reference to unaudited consolidated management accounts of the Group for the six months ended 30 September 2024 and the information currently available to the Board. Such information has not been reviewed and confirmed by the auditor of the Company, and may be subject to adjustments. Further details of the Group's performance will be disclosed in the interim results announcement of the Company for the six months ended 30 September 2024 in accordance with the Listing Rules, which is expected to be published on 19 November 2024.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**JBM (Healthcare) Limited**  
**YU Chun Kau**  
*Company Secretary*

Hong Kong, 1 November 2024

*As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek as the Chairman and non-executive Director, Mr. Wong Yat Wai, Patrick (also as Chief Executive Officer) and Dr. Cheng Celine Heung Kwan as executive Directors, Mr. Yim Chun Leung and Mr. Yeung Kwok Chun, Harry as non-executive Directors, and Mr. Chan Kam Chiu, Simon, Mr. Luk Ting Lung, Alan and Mr. Lau Shut Lee, Tony as independent non-executive Directors.*